Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | MC4R | P32245 | 1/20 | 0.68 |
| ▸ | CHKA | P35790 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | NCF1 | P14598 | 1/20 | 0.61 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL3589945 | 0.98 | LMNA (0.69) | LMNAALDH1A1POLBMC4RCHKA | |
| SCHEMBL19225381 | 0.94 | CHKA (0.74) | LMNAALDH1A1POLBMC4RCHKA | |
| SCHEMBL13246320 | 0.93 | CHKA (0.77) | LMNAALDH1A1POLBMC4RCHKA | |
| SCHEMBL11356824 | 0.91 | LMNA (0.83) | LMNAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL7989269 | 0.91 | LMNA (0.83) | LMNAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL1045922 | 0.91 | LMNA (0.83) | LMNAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL7989530 | 0.91 | LMNA (0.83) | LMNAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL14409689 | 0.89 | LMNA (0.59) | LMNAALDH1A1POLBMC4RCHKA | |
| SCHEMBL17465321 | 0.88 | CHKA (0.87) | LMNAALDH1A1POLBCHKACA2 | |
| SCHEMBL1045595 | 0.85 | ALDH1A1 (0.74) | LMNAALDH1A1POLBCHKAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112692-A1 | CASITAS B-LINEAGE LYMPHOMA PROTOONCOGENE B (CBL-B) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2023237759-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR | ANAGENESIS BIOTECHNOLOGIES (FR) | 2023-12-14 | — | — | WO | disclosed |
| EP-4289835-A1 | CDK INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| EP-2713736-B1 | NOVEL IMMUNE SYSTEM MODULATORS | JANUS BIOTHERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3675858-B1 | IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | OPTIKIRA LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | Impact Therapeutics (Shanghai), Inc (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20070191267-A1 | Use of tyrosine kinase inhibitors for treating cerebral ischemia | AB SCIENCE | 2007-08-16 | — | — | US | disclosed |
| WO-2007081835-A2 | MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES | BTG INTERNATIONAL LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| WO-2007026251-A2 | USE OF DUAL C-KIT/FGFR3 INHIBITORS FOR TREATING MULTIPLE MYELOMA | AB SCIENCE (FR) | 2007-03-08 | — | — | WO | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | AB SCIENCE | 2007-02-08 | — | — | US | disclosed |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | AB SCIENCE | 2007-02-08 | — | — | US | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | LMNA 3914/4885ALDH1A1 4351/4885POLB 3037/4885 |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | KIT, CPA3, CMA1 | LMNA 3211/4885ALDH1A1 1266/4885POLB 4465/4885 |
| US-20070191267-A1 | Use of tyrosine kinase inhibitors for treating cerebral ischemia | KIT, MAST3, CPA3 | LMNA 4130/4885ALDH1A1 2190/4885POLB 4745/4885 |
| US-11345711-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | LMNA 3833/4885ALDH1A1 1361/4885POLB 2249/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | LMNA 4087/4885ALDH1A1 904/4885POLB 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.